Background The clinical course of prostate cancer (PCa) is highly variable, demanding an
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …

… Doris Höflmayer …

Purpose Expansion of CD8 + cytotoxic Tlymphocytes is a prerequisite for anti-cancer immune
activity and has gained interest in the era of immune checkpoint therapy. Methods To …

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures
for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its …

Background Nodal metastasis (N1) is a strong prognostic parameter in prostate cancer;
however, lymph node evaluation is always incomplete. Objective To study the prognostic value …

Background Cytokeratin 18 (CK18) is an intermediate filament protein of the cytokeratin acidic
type I group and is primarily expressed in single-layered or “simple” epithelial tissues and …

TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel immune
therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and …

Syndecan-1 (CD138) is a transmembrane proteoglycan known to be expressed in various
normal and malignant tissues. It is of interest because of a possible prognostic role of …

p16 (CDKN2A) is a member of the INK4 class of cell cycle inhibitors, which is often
dysregulated in cancer. However, the prevalence of p16 expression in different cancer types is …

Introduction: Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan,
an antibody-drug conjugate approved for treatment of triple negative breast cancer and …